NL192870C - Anti-hypertensief oraal farmaceutisch preparaat. - Google Patents
Anti-hypertensief oraal farmaceutisch preparaat. Download PDFInfo
- Publication number
- NL192870C NL192870C NL7812164A NL7812164A NL192870C NL 192870 C NL192870 C NL 192870C NL 7812164 A NL7812164 A NL 7812164A NL 7812164 A NL7812164 A NL 7812164A NL 192870 C NL192870 C NL 192870C
- Authority
- NL
- Netherlands
- Prior art keywords
- day
- hydrochlorothiazide
- blood pressure
- hours
- administered
- Prior art date
Links
- 230000003276 anti-hypertensive effect Effects 0.000 title description 2
- 239000008183 oral pharmaceutical preparation Substances 0.000 title description 2
- ZZUFCTLCJUWOSV-UHFFFAOYSA-N furosemide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C(O)=O)=C1NCC1=CC=CO1 ZZUFCTLCJUWOSV-UHFFFAOYSA-N 0.000 claims description 15
- 229960003883 furosemide Drugs 0.000 claims description 15
- JZUFKLXOESDKRF-UHFFFAOYSA-N Chlorothiazide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC2=C1NCNS2(=O)=O JZUFKLXOESDKRF-UHFFFAOYSA-N 0.000 claims description 12
- 229960002003 hydrochlorothiazide Drugs 0.000 claims description 12
- 229960002429 proline Drugs 0.000 claims description 12
- 241000700159 Rattus Species 0.000 claims description 11
- 230000036772 blood pressure Effects 0.000 claims description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 9
- 150000001875 compounds Chemical class 0.000 claims description 8
- 238000002360 preparation method Methods 0.000 claims description 7
- 206010020772 Hypertension Diseases 0.000 claims description 5
- 239000003814 drug Substances 0.000 claims description 5
- 238000011282 treatment Methods 0.000 claims description 5
- 239000002552 dosage form Substances 0.000 claims description 4
- 239000002220 antihypertensive agent Substances 0.000 claims description 3
- 230000001631 hypertensive effect Effects 0.000 claims description 3
- 239000000523 sample Substances 0.000 claims description 3
- 229940127088 antihypertensive drug Drugs 0.000 claims description 2
- 229940079593 drug Drugs 0.000 claims description 2
- QSHDDOUJBYECFT-UHFFFAOYSA-N mercury Chemical compound [Hg] QSHDDOUJBYECFT-UHFFFAOYSA-N 0.000 claims description 2
- 229910052753 mercury Inorganic materials 0.000 claims description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims 2
- 239000012153 distilled water Substances 0.000 claims 2
- 230000010349 pulsation Effects 0.000 claims 2
- 229940126062 Compound A Drugs 0.000 claims 1
- NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 claims 1
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 claims 1
- 238000009530 blood pressure measurement Methods 0.000 claims 1
- 230000001684 chronic effect Effects 0.000 claims 1
- 230000008034 disappearance Effects 0.000 claims 1
- 210000003734 kidney Anatomy 0.000 claims 1
- 229920000609 methyl cellulose Polymers 0.000 claims 1
- 239000001923 methylcellulose Substances 0.000 claims 1
- 235000010981 methylcellulose Nutrition 0.000 claims 1
- 210000002254 renal artery Anatomy 0.000 claims 1
- 229910052709 silver Inorganic materials 0.000 claims 1
- 239000004332 silver Substances 0.000 claims 1
- 230000035488 systolic blood pressure Effects 0.000 claims 1
- 230000003442 weekly effect Effects 0.000 claims 1
- FAKRSMQSSFJEIM-RQJHMYQMSA-N captopril Chemical compound SC[C@@H](C)C(=O)N1CCC[C@H]1C(O)=O FAKRSMQSSFJEIM-RQJHMYQMSA-N 0.000 description 17
- 229960000830 captopril Drugs 0.000 description 16
- 239000003826 tablet Substances 0.000 description 13
- 239000002934 diuretic Substances 0.000 description 11
- 230000001882 diuretic effect Effects 0.000 description 10
- 239000000203 mixture Substances 0.000 description 9
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 8
- 239000008101 lactose Substances 0.000 description 8
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 6
- 229920002261 Corn starch Polymers 0.000 description 5
- 235000021355 Stearic acid Nutrition 0.000 description 5
- 239000008120 corn starch Substances 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 5
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 5
- 239000008117 stearic acid Substances 0.000 description 5
- 239000005541 ACE inhibitor Substances 0.000 description 4
- 229920001817 Agar Polymers 0.000 description 4
- 239000008272 agar Substances 0.000 description 4
- 229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 description 4
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 3
- 239000013543 active substance Substances 0.000 description 3
- 235000019359 magnesium stearate Nutrition 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- 229910052708 sodium Inorganic materials 0.000 description 3
- 238000011699 spontaneously hypertensive rat Methods 0.000 description 3
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 239000007903 gelatin capsule Substances 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- FAKRSMQSSFJEIM-COBSHVIPSA-N (2r)-1-(2-methyl-3-sulfanylpropanoyl)pyrrolidine-2-carboxylic acid Chemical compound SCC(C)C(=O)N1CCC[C@@H]1C(O)=O FAKRSMQSSFJEIM-COBSHVIPSA-N 0.000 description 1
- UUUHXMGGBIUAPW-UHFFFAOYSA-N 1-[1-[2-[[5-amino-2-[[1-[5-(diaminomethylideneamino)-2-[[1-[3-(1h-indol-3-yl)-2-[(5-oxopyrrolidine-2-carbonyl)amino]propanoyl]pyrrolidine-2-carbonyl]amino]pentanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-3-methylpentanoyl]pyrrolidine-2-carbon Chemical compound C1CCC(C(=O)N2C(CCC2)C(O)=O)N1C(=O)C(C(C)CC)NC(=O)C(CCC(N)=O)NC(=O)C1CCCN1C(=O)C(CCCN=C(N)N)NC(=O)C1CCCN1C(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C1CCC(=O)N1 UUUHXMGGBIUAPW-UHFFFAOYSA-N 0.000 description 1
- 241000220479 Acacia Species 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 102100030988 Angiotensin-converting enzyme Human genes 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- QGMRQYFBGABWDR-UHFFFAOYSA-M Pentobarbital sodium Chemical compound [Na+].CCCC(C)C1(CC)C(=O)NC(=O)[N-]C1=O QGMRQYFBGABWDR-UHFFFAOYSA-M 0.000 description 1
- 108090000882 Peptidyl-Dipeptidase A Proteins 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- 206010041277 Sodium retention Diseases 0.000 description 1
- UUUHXMGGBIUAPW-CSCXCSGISA-N Teprotide Chemical compound N([C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(O)=O)C(=O)[C@@H]1CCC(=O)N1 UUUHXMGGBIUAPW-CSCXCSGISA-N 0.000 description 1
- 108010045759 Teprotide Proteins 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 150000001447 alkali salts Chemical class 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 229940030600 antihypertensive agent Drugs 0.000 description 1
- 230000004872 arterial blood pressure Effects 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000001447 compensatory effect Effects 0.000 description 1
- 230000035619 diuresis Effects 0.000 description 1
- 229940030606 diuretics Drugs 0.000 description 1
- 238000007580 dry-mixing Methods 0.000 description 1
- 239000004744 fabric Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 229940082195 hydrochlorothiazide 12.5 mg Drugs 0.000 description 1
- 229940082205 hydrochlorothiazide 25 mg Drugs 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- -1 mercapto-2-methylpropanoyl Chemical group 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 229960002275 pentobarbital sodium Drugs 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 150000003147 proline derivatives Chemical class 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 229950010186 teprotide Drugs 0.000 description 1
- 238000011706 wistar kyoto rat Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
- A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
- A61K31/585—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin containing lactone rings, e.g. oxandrolone, bufalin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Heart & Thoracic Surgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Cardiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US86442877A | 1977-12-27 | 1977-12-27 | |
| US86442877 | 1977-12-27 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| NL7812164A NL7812164A (nl) | 1979-06-29 |
| NL192870B NL192870B (nl) | 1997-12-01 |
| NL192870C true NL192870C (nl) | 1998-04-02 |
Family
ID=25343256
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NL7812164A NL192870C (nl) | 1977-12-27 | 1978-12-14 | Anti-hypertensief oraal farmaceutisch preparaat. |
| NL980017C NL980017I1 (nl) | 1977-12-27 | 1998-04-24 | Anti-hypertensief oraal farmaceutisch preparaat. |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NL980017C NL980017I1 (nl) | 1977-12-27 | 1998-04-24 | Anti-hypertensief oraal farmaceutisch preparaat. |
Country Status (30)
| Country | Link |
|---|---|
| JP (1) | JPS54110333A (en, 2012) |
| AR (1) | AR230378A1 (en, 2012) |
| AU (1) | AU526239B2 (en, 2012) |
| BE (1) | BE873092A (en, 2012) |
| CA (1) | CA1120400A (en, 2012) |
| CH (1) | CH642542A5 (en, 2012) |
| DE (1) | DE2854316C3 (en, 2012) |
| DK (1) | DK578778A (en, 2012) |
| EG (1) | EG14178A (en, 2012) |
| FI (1) | FI783991A7 (en, 2012) |
| FR (1) | FR2413089A1 (en, 2012) |
| GB (1) | GB2010675B (en, 2012) |
| GR (1) | GR72951B (en, 2012) |
| HK (1) | HK45483A (en, 2012) |
| HU (1) | HU178747B (en, 2012) |
| IE (1) | IE48306B1 (en, 2012) |
| IL (1) | IL56281A (en, 2012) |
| IT (1) | IT1202811B (en, 2012) |
| KE (1) | KE3235A (en, 2012) |
| LU (1) | LU80709A1 (en, 2012) |
| MY (2) | MY8300240A (en, 2012) |
| NL (2) | NL192870C (en, 2012) |
| NO (1) | NO784357L (en, 2012) |
| NZ (1) | NZ189159A (en, 2012) |
| PH (1) | PH22111A (en, 2012) |
| PL (1) | PL212188A1 (en, 2012) |
| PT (1) | PT68983A (en, 2012) |
| SE (1) | SE445173B (en, 2012) |
| SG (1) | SG41482G (en, 2012) |
| ZA (1) | ZA786948B (en, 2012) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5829950B2 (ja) * | 1978-10-05 | 1983-06-25 | ウェルファイド株式会社 | 環状イミノカルボン酸誘導体およびその塩類 |
| US4350704A (en) | 1980-10-06 | 1982-09-21 | Warner-Lambert Company | Substituted acyl derivatives of octahydro-1H-indole-2-carboxylic acids |
| US4482725A (en) * | 1980-04-03 | 1984-11-13 | E. R. Squibb & Sons, Inc. | S-Acylation products of mercaptoacyl amino acids and carboxyl group containing diuretics |
| US4344949A (en) | 1980-10-03 | 1982-08-17 | Warner-Lambert Company | Substituted acyl derivatives of 1,2,3,4-tetrahydroisoquinoline-3-carboxylic acids |
| US4532342A (en) * | 1981-02-20 | 1985-07-30 | Warner-Lambert Company | N-substituted amino acids as intermediates in the preparation of acyl derivatives of 1,2,3,4-tetrahydroisoquinoline-3-carboxylic acids |
| US4552889A (en) * | 1983-06-09 | 1985-11-12 | Eli Lilly And Company | 3-Mercaptomethyl-2-oxo-1-pyrrolidine acetic acids and use for hypertension |
| US4898729A (en) * | 1983-12-09 | 1990-02-06 | Euroceltique, S.A. | Treatment of hypertension, compounds and compositions for antihypertension and diuresis |
| DE3532036A1 (de) * | 1985-09-09 | 1987-03-26 | Hoechst Ag | Pharmazeutische zubereitung zur behandlung des bluthochdrucks |
| DK9200258U4 (da) * | 1992-03-11 | 1993-07-23 | Merck & Co Inc | Farmaceutisk præparat indeholdende enalapril til brug mod hypertension |
| WO1996024358A1 (en) * | 1995-02-10 | 1996-08-15 | G.D. Searle & Co. | Use of low dose amount of spironolactone for treatment of cardiovascular disease |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU509899B2 (en) * | 1976-02-13 | 1980-05-29 | E.R. Squibb & Sons, Inc. | Proline derivatives and related compounds |
-
1978
- 1978-11-21 CA CA000316609A patent/CA1120400A/en not_active Expired
- 1978-11-29 AU AU42041/78A patent/AU526239B2/en not_active Expired
- 1978-12-06 IE IE2413/78A patent/IE48306B1/en unknown
- 1978-12-06 FR FR7834359A patent/FR2413089A1/fr active Granted
- 1978-12-12 ZA ZA786948A patent/ZA786948B/xx unknown
- 1978-12-13 NZ NZ189159A patent/NZ189159A/en unknown
- 1978-12-14 NL NL7812164A patent/NL192870C/nl not_active IP Right Cessation
- 1978-12-14 GR GR57879A patent/GR72951B/el unknown
- 1978-12-14 CH CH1273778A patent/CH642542A5/de not_active IP Right Cessation
- 1978-12-15 DE DE2854316A patent/DE2854316C3/de not_active Expired - Lifetime
- 1978-12-19 PH PH21971A patent/PH22111A/en unknown
- 1978-12-21 GB GB7849703A patent/GB2010675B/en not_active Expired
- 1978-12-22 HU HU78SU1000A patent/HU178747B/hu unknown
- 1978-12-22 NO NO784357A patent/NO784357L/no unknown
- 1978-12-22 DK DK578778A patent/DK578778A/da not_active Application Discontinuation
- 1978-12-22 IL IL56281A patent/IL56281A/xx unknown
- 1978-12-22 LU LU80709A patent/LU80709A1/de unknown
- 1978-12-22 SE SE7813277A patent/SE445173B/sv not_active IP Right Cessation
- 1978-12-22 IT IT31266/78A patent/IT1202811B/it active Protection Beyond IP Right Term
- 1978-12-25 EG EG740/78A patent/EG14178A/xx active
- 1978-12-25 JP JP16462778A patent/JPS54110333A/ja active Granted
- 1978-12-26 PT PT68983A patent/PT68983A/pt unknown
- 1978-12-27 FI FI783991A patent/FI783991A7/fi unknown
- 1978-12-27 BE BE192574A patent/BE873092A/xx not_active IP Right Cessation
- 1978-12-27 PL PL21218878A patent/PL212188A1/xx unknown
- 1978-12-27 AR AR274975A patent/AR230378A1/es active
-
1982
- 1982-09-02 SG SG414/82A patent/SG41482G/en unknown
- 1982-09-14 KE KE3235A patent/KE3235A/xx unknown
-
1983
- 1983-10-20 HK HK454/83A patent/HK45483A/xx not_active IP Right Cessation
- 1983-12-30 MY MY240/83A patent/MY8300240A/xx unknown
-
1987
- 1987-10-31 MY MYPI87003001A patent/MY102991A/en unknown
-
1998
- 1998-04-24 NL NL980017C patent/NL980017I1/nl unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US4217347A (en) | Method of treating hypertension and medicaments therefor | |
| NL192870C (nl) | Anti-hypertensief oraal farmaceutisch preparaat. | |
| CZ177397A3 (en) | Use of frank incense for preparing a medicament for prophylactic and therapeutic treatment of alzheimer's disease | |
| Plänitz | Comparison of moxonidine and clonidine HCl in treating patients with hypertension | |
| EP0629400B1 (en) | Idebenone compositions for treating Alzheimer's disease | |
| HUP0300917A2 (hu) | Bradikardiakumok alkalmazása hipertrófiával társult miokardiális betegségek kezelésére és ezeket tartalmazó gyógyszerkészítmények | |
| WO2001056609A1 (de) | Pharmazeutische zusammensetzung für die behandlung einer durch arzneimittel induzierten hyperhomocysteinämie | |
| DE69712338T2 (de) | Zusammensetzung auf basis von enalapril und losartan | |
| EP0005015B1 (en) | Use of a xanthine derivate in the manufacture of a medicament | |
| EP2837380B1 (en) | Lercanidipine hydrochloride and losartan potassium compound preparation and preparation method thereof | |
| US4225607A (en) | Pharmaceutical composition containing a xanthine derivative | |
| DK165966B (da) | Forbedret piroxicamholdigt anti-inflammatorisk praeparat | |
| JPS626687B2 (en, 2012) | ||
| JP2584636B2 (ja) | 胃炎治療剤 | |
| DE3888827T2 (de) | Behandlung von arteriosklerosis durch verabreichung von l-tryptophane oder l-5-hydroxytryptophan. | |
| Wiseman et al. | Development of a sustained‐release aspirin tablet | |
| JPH0251885B2 (en, 2012) | ||
| JP3024789B2 (ja) | 血圧降下剤 | |
| EP0576452B1 (de) | Erzeugnisse, enthaltend verapamil und trandolapril | |
| JPS58140017A (ja) | 心不全治療剤 | |
| KR20010019397A (ko) | 발기부전 치료용 조성물 | |
| GB2141027A (en) | Diltiazem hypolipidemic compositions | |
| RU2183117C1 (ru) | Средство для нормализации артериального давления и способ лечения гипертонической болезни | |
| DE68912159T2 (de) | Dioxoquinazolinderivat enthaltendes Antihypertensivum. | |
| EP0005733A1 (en) | Pharmaceutical compositions for use in the treatment of diabetic nephropathy and method for preparing them |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A85 | Still pending on 85-01-01 | ||
| BA | A request for search or an international-type search has been filed | ||
| BB | A search report has been drawn up | ||
| BC | A request for examination has been filed | ||
| AC1 | Application for a supplementary protection certificate |
Free format text: 980017, 980424 |
|
| BC1 | Further communications concerning applications for a supplementary protection certificate |
Free format text: 980017 |
|
| BC1 | Further communications concerning applications for a supplementary protection certificate |
Free format text: 980017 |
|
| V4 | Discontinued because of reaching the maximum lifetime of a patent |
Free format text: 981214 |